Actor and Comedian Chris Tucker Partners With The Prostate Cancer Foundation During National Minority Health Month to Create Awareness About the Increased Risks for African-American Men and Challenges Them to “Know the Numbers”
SANTA MONICA, Calif., April 3, 2018 -- The Prostate Cancer Foundation (PCF) announced today that actor, comedian and humanitarian Chris Tucker (Rush Hour) will join its National Minority Health Month initiative as a spokesperson...Read More
Scientists uncover “long tail” of nearly 100 genes mutated in prostate cancer
APRIL 2, 2018 -- Issued by Dana-Farber Cancer Institute. By sequencing DNA in more than 1,000 patient samples, researchers have identified a total of 97 genes significantly mutated in prostate...Read More
New Study indicates 18 months of androgen deprivation therapy may be optimal for locally advanced prostate cancer
Results from the RADAR clinical trial presented at the 2018 ASCO Genitourinary Cancer Symposium indicate that 18 months of ADT could very likely become the new standard of care. The...Read More
Kristen Bell Chooses Winners of The Prostate Cancer Foundation’s 1st Annual TRUE Love Campaign Honoring Caregivers of Prostate Cancer Patients
SANTA MONICA, Calif., March 13, 2018 – The winners of the 1st Annual TRUE Love Campaign honoring caregivers of prostate cancer patients were announced today by the Prostate Cancer Foundation...Read More
New NCCN Guidelines Incorporate PCF-Funded Research on Cancer Risk Genes
Thanks in large part to the kinds of genetic and precision medicine that the Prostate Cancer Foundation has been funding, the National Comprehensive Cancer Network (NCCN) has issued updated prostate...Read More
Prostate Cancer Loves Couch Potatoes
Hey, guys: If you think exercise is just about pumping iron and getting big traps, six-pack abs and “gun show” biceps, your prostate would like to disagree. To your prostate,...Read More
FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer
February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). This...Read More
Blood Profiling Atlas in Cancer Consortium (BloodPAC) Announces Milestone in Accelerating Development of Liquid Biopsy for Cancer: Initial Release of Open Data
CHICAGO – Exactly one year after its establishment as an independent non-profit, The Blood Profiling Atlas in Cancer Consortium (BloodPAC) announced the public release and accessibility of an initial dataset....Read More
Two new treatments have been found for prostate cancer patients who previously had no effective treatment options
Over the course of prostate cancer progression, there can come a time during which the cancer is progressing, but there are no treatments known to improve survival. One of these...Read More
FDA approves Abiraterone + Prednisone for Earlier Treatment of Metastatic Prostate Cancer
Back in June, we told you about the early results of the LATITUDE clinical trial, presented at the 2017 ASCO conference. The study indicated that giving abiraterone in combination with...Read More